Skip to main content
SpringerLink
Log in

Cannabinoids: Potential Targets for Bladder Dysfunction

  • Chapter
  • First Online:
Urinary Tract

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 2011))

Abstract

Cannabinoids are the active chemical components of Cannabis sativa (marijuana). The medical use of cannabis goes back over 5,000 years. Cannabinoids produce a very wide array of central and peripheral effects, some of which may have beneficial clinical applications. The discovery of cannabinoid receptors has spawned great interest within the pharmaceutical industry with the hopes of capitalizing on the beneficial effects of cannabis without the unwanted psychotropic effects on the central and peripheral nervous system. This chapter presents an overview of the pharmacology of cannabinoids and their derivatives. It reviews the current literature on central and peripheral cannabinoid receptors as related to effects on the lower urinary tract and the role of these receptors in normal and abnormal urinary tract function. An objective evaluation of the published results of clinical trials of cannabis extracts for the treatment of bladder dysfunction resulting from multiple sclerosis is also presented. It is clear that cannabinoid receptors are present in the lower urinary tract as well as spinal and higher centers involved in lower urinary tract control. Systemic cannabinoids have effects on the lower urinary tract that may be able to become clinically useful; however, a much greater understanding of the mechanisms of cannabinoid receptors in control of the human lower urinary tract is necessary to facilitate development of novel cannabinoid drugs for treatment of pelvic disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • Apodaca G, Balestreire E, Birder LA (2007) The uroepithelial-associated sensory web. Kidney Int 72(9):1057–1064

    CAS  PubMed  Google Scholar 

  • Ashton JC, Ashton JC (2007) Cannabinoids for the treatment of inflammation. Curr Opin Invest Drugs 8(5):373–384

    CAS  Google Scholar 

  • Ashton JC, Smith PF, Ashton JC, Smith PF (2007) Cannabinoids and cardiovascular disease: the outlook for clinical treatments. Curr Vasc Pharmacol 5(3):175–185

    CAS  PubMed  Google Scholar 

  • Avelino A, Cruz C, Nagy I, Cruz F (2002) Vanilloid receptor 1 expression in the rat urinary tract. Neuroscience 109(4):787–798

    CAS  PubMed  Google Scholar 

  • Baker D, Pryce G, Giovannoni G, Thompson AJ (2003) The therapeutic potential of cannabis. Lancet Neurol 2(5):291–298

    CAS  PubMed  Google Scholar 

  • Bayewitch M, Rhee MH, Avidor-Reiss T, Breuer A, Mechoulam R, Vogel Z (1996) (−)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J Biol Chem 271(17):9902–9905

    CAS  PubMed  Google Scholar 

  • Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee MH, Vogel Z et al (1998) An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol 353(1):23–31

    CAS  PubMed  Google Scholar 

  • Birder LA, de Groat WC (1992) Increased c-fos expression in spinal neurons after irritation of the lower urinary tract in the rat. J Neurosci 12(12):4878–4889

    CAS  PubMed  Google Scholar 

  • Bodei S, Arrighi N, Spano P, Sigala S, Bodei S, Arrighi N et al (2009) Should we be cautious on the use of commercially available antibodies to dopamine receptors? Naunyn Schmiedebergs Arch Pharmacol 379(4):413–415

    CAS  PubMed  Google Scholar 

  • Bonhaus DW, Chang LK, Kwan J, Martin GR (1998) Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J Pharmacol Exp Ther 287(3):884–888

    CAS  PubMed  Google Scholar 

  • Bowery NG, Hudson AL, Price GW (1987) GABAA and GABAB receptor site distribution in the rat central nervous system. Neuroscience 20(2):365–383

    CAS  PubMed  Google Scholar 

  • Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, Fowler CJ (2004) An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. [see comment]. Mult Scler 10(4):425–433

    CAS  PubMed  Google Scholar 

  • Busch-Petersen J, Hill WA, Fan P, Khanolkar A, Xie XQ, Tius MA et al (1996) Unsaturated side chain beta-11-hydroxyhexahydrocannabinol analogs. J Med Chem 39(19):3790–3796

    CAS  PubMed  Google Scholar 

  • Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D (1997) The capsaicin receptor: a heat-activated ion channel in the pain pathway. [see comment]. Nature 389(6653):816–824

    CAS  PubMed  Google Scholar 

  • Consroe P, Musty R, Rein J, Tillery W, Pertwee R (1997) The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 38(1):44–48

    CAS  PubMed  Google Scholar 

  • Cox PJ (1979) Cyclophosphamide cystitis – identification of acrolein as the causative agent. Biochem Pharmacol 28(13):2045–2049

    CAS  PubMed  Google Scholar 

  • De Petrocellis L, Chu CJ, Moriello AS, Kellner JC, Walker JM, Di Marzo V et al (2004) Actions of two naturally occurring saturated N-acyldopamines on transient receptor potential vanilloid 1 (TRPV1) channels. Br J Pharmacol 143(2):251–256

    PubMed  Google Scholar 

  • De Smet PA (1997) The role of plant-derived drugs and herbal medicines in healthcare. Drugs 54(6):801–840

    CAS  PubMed  Google Scholar 

  • Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34(5):605–613

    CAS  PubMed  Google Scholar 

  • Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G et al (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. [see comment]. Science 258(5090):1946–1949

    CAS  PubMed  Google Scholar 

  • Dewey WL (1986) Cannabinoid pharmacology. Pharmacol Rev 38(2):151–178

    CAS  PubMed  Google Scholar 

  • Di Marzo V, Melck D, Bisogno T, De Petrocellis L (1998) Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci 21(12):521–528 [erratum appears in Trends Neurosci 1999 Feb;22(2):80]

    PubMed  Google Scholar 

  • Di Marzo V, Bisogno T, De Petrocellis L, Brandi I, Jefferson RG, Winckler RL et al (2001) Highly selective CB(1) cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor “hybrid” ligands. Biochem Biophys Res Commun 281(2):444–451

    PubMed  Google Scholar 

  • di Tomaso E, Beltramo M, Piomelli D (1996) Brain cannabinoids in chocolate. Nature 382(6593):677–678 [see comment]

    PubMed  Google Scholar 

  • Dinh TP, Freund TF, Piomelli D, Dinh TP, Freund TF, Piomelli D (2002) A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids 121(1–2):149–158

    CAS  PubMed  Google Scholar 

  • Dinis P, Charrua A, Avelino A, Yaqoob M, Bevan S, Nagy I et al (2004a) Anandamide-evoked activation of vanilloid receptor 1 contributes to the development of bladder hyperreflexia and nociceptive transmission to spinal dorsal horn neurons in cystitis. J Neurosci 24(50):11253–11263

    CAS  PubMed  Google Scholar 

  • Dinis P, Charrua A, Avelino A, Cruz F, Dinis P, Charrua A et al (2004b) Intravesical resiniferatoxin decreases spinal c-fos expression and increases bladder volume to reflex micturition in rats with chronic inflamed urinary bladders. BJU Int 94(1):153–157

    PubMed  Google Scholar 

  • Dmitrieva N, Shelton D, Rice AS, McMahon SB (1997) The role of nerve growth factor in a model of visceral inflammation. Neuroscience 78(2):449–459

    CAS  PubMed  Google Scholar 

  • Dyson A, Peacock M, Chen A, Courade JP, Yaqoob M, Groarke A et al (2005) Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat. Pain 116(1–2):129–137

    CAS  PubMed  Google Scholar 

  • Egertova M, Elphick MR (2000) Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB. J Comp Neurol 422(2):159–171

    CAS  PubMed  Google Scholar 

  • Egertova M, Giang DK, Cravatt BF, Elphick MR (1998) A new perspective on cannabinoid signalling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. Proc R Soc Lond Ser B Biol Sci 265(1410):2081–2085

    CAS  Google Scholar 

  • Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A (1995) Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA 92(8):3376–3380

    CAS  PubMed  Google Scholar 

  • Farquhar-Smith WP, Jaggar SI, Rice AS, Farquhar-Smith WP, Jaggar SI, Rice ASC (2002) Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors. Pain 97(1–2):11–21

    CAS  PubMed  Google Scholar 

  • Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O et al (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48(3):443–450

    CAS  PubMed  Google Scholar 

  • Felder CC, Joyce KE, Briley EM, Glass M, Mackie KP, Fahey KJ et al (1998) LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J Pharmacol Exp Ther 284(1):291–297

    CAS  PubMed  Google Scholar 

  • Fezza F, Bisogno T, Minassi A, Appendino G, Mechoulam R, Di Marzo V et al (2002) Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett 513(2–3):294–298

    CAS  PubMed  Google Scholar 

  • Freeman RM, Adekanmi O, Waterfield MR, Waterfield AE, Wright D, Zajicek J (2006) The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int Urogynecol J 17(6):636–641

    CAS  Google Scholar 

  • Fry CH, Byliss M, Pirolo JS, Ikeda Y, Hussain M (2010) The influence of age, gender and bladder dysfunction on the contractile properties of isolated human detrusor smooth muscle. BJU Int in press, first published online: 11 Nov 2010, doi: 10.1111/j.1464-410X.2010.09845.x

  • Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P et al (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232(1):54–61

    CAS  PubMed  Google Scholar 

  • Gallant M, Dufresme C, Girard Y, Gual D, Leblanc Y, Prasit P et al (1996) New class of potent ligands for the human peripheral cannabinoid receptor. Bioorg Med Chem Lett 6(19):2263–2268

    CAS  Google Scholar 

  • Garcia MdC, Adler-Graschinsky E, Celuch SM (2009) Enhancement of the hypotensive effects of intrathecally injected endocannabinoids by the entourage compound palmitoylethanolamide. Eur J Pharmacol 610(1–3):75–80

    CAS  Google Scholar 

  • Gareau Y, Dufresne C, Gallant M, Rochette C, Sawyer N, Slipetz DM et al (1996) Structure activity relationships of tetrahydrocannabinol analogues on human cannabinoid receptors. Bioorg Med Chem Lett 6(2):189–194

    CAS  Google Scholar 

  • Glass M, Dragunow M, Faull RL (1997) Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77(2):299–318

    CAS  PubMed  Google Scholar 

  • Gong JP, Onaivi ES, Ishiguro H, Liu QR, Tagliaferro PA, Brusco A et al (2006) Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 1071(1):10–23

    CAS  PubMed  Google Scholar 

  • Gratzke C, Streng T, Park A, Christ G, Stief CG, Hedlund P et al (2009) Distribution and function of cannabinoid receptors 1 and 2 in the rat, monkey and human bladder. J Urol 181(4):1939–1948

    CAS  PubMed  Google Scholar 

  • Greenamyre JT, Young AB, Penney JB (1984) Quantitative autoradiographic distribution of L-[3H]glutamate-binding sites in rat central nervous system. J Neurosci 4(8):2133–2144

    CAS  PubMed  Google Scholar 

  • Griffin G, Wray EJ, Tao Q, McAllister SD, Rorrer WK, Aung MM et al (1999) Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system. Eur J Pharmacol 377(1):117–125

    CAS  PubMed  Google Scholar 

  • Grotenhermen F, Grotenhermen F (2004) Pharmacology of cannabinoids. Neuroendocrinol Lett 25(1–2):14–23

    CAS  PubMed  Google Scholar 

  • Grotenhermen F, Grotenhermen F (2005) Cannabinoids. Curr Drug Targets CNS Neurol Disord 4(5):507–530

    CAS  PubMed  Google Scholar 

  • Hajos N, Katona I, Naiem SS, MacKie K, Ledent C, Mody I et al (2000) Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. Eur J Neurosci 12(9):3239–3249

    CAS  PubMed  Google Scholar 

  • Hamdani N, van der Velden J, Hamdani N, van der Velden J (2009) Lack of specificity of antibodies directed against human beta-adrenergic receptors. Naunyn Schmiedebergs Arch Pharmacol 379(4):403–407 [Erratum appears in Naunyn Schmiedebergs Arch Pharmacol. 2009 Jun;379(6):637]

    CAS  PubMed  Google Scholar 

  • Hanus L, Gopher A, Almog S, Mechoulam R (1993) Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem 36(20):3032–3034

    CAS  PubMed  Google Scholar 

  • Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M et al (1999) HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 96(25):14228–14233

    CAS  PubMed  Google Scholar 

  • Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE et al (2001) 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 98(7):3662–3665

    CAS  PubMed  Google Scholar 

  • Hayn MH, Ballesteros I, de Miguel F, Coyle CH, Tyagi S, Yoshimura N et al (2008) Functional and immunohistochemical characterization of CB1 and CB2 receptors in rat bladder. Urology 72(5):1174–1178

    PubMed  Google Scholar 

  • Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR et al (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87(5):1932–1936

    CAS  PubMed  Google Scholar 

  • Hillard CJ, Manna S, Greenberg MJ, DiCamelli R, Ross RA, Stevenson LA et al (1999) Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther 289(3):1427–1433

    CAS  PubMed  Google Scholar 

  • Hiragata S, Ogawa T, Hayashi Y, Tyagi P, Seki S, Nishizawa O et al (2007) Effects of IP-751, ajulemic acid, on bladder overactivity induced by bladder irritation in rats. Urology 70(1):202–208

    PubMed  Google Scholar 

  • Ho WS, Barrett DA, Randall MD, Ho WSV (2008) ‘Entourage’ effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors. Br J Pharmacol 155(6):837–846

    CAS  PubMed  Google Scholar 

  • Hollister LE (1986) Health aspects of cannabis. Pharmacol Rev 38(1):1–20

    CAS  PubMed  Google Scholar 

  • Holzer P (2004) TRPV1 and the gut: from a tasty receptor for a painful vanilloid to a key player in hyperalgesia. Eur J Pharmacol 500(1–3):231–241

    CAS  PubMed  Google Scholar 

  • Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA et al (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54(2):161–202

    CAS  PubMed  Google Scholar 

  • Huffman JW, Yu S, Showalter V, Abood ME, Wiley JL, Compton DR et al (1996) Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. J Med Chem 39(20):3875–3877

    CAS  PubMed  Google Scholar 

  • Huffman JW, Yu S, Liddle J, Wiley JL, Abood M, Martin BR et al (eds) (1999) 1-Deoxy-1_,1_dimethylalkyl-_8-THC derivatives: selective ligands for the CB2 receptor. In: 1999 Symposium on the Cannabinoids 1998. International Cannabinoid Research Society, Acapulco, Mexico, Burlington, Vermont

    Google Scholar 

  • Huffman JW, Liddle J, Yu S, Aung MM, Abood ME, Wiley JL et al (1999b) 3-(1′, 1′-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem 7(12):2905–2914

    CAS  PubMed  Google Scholar 

  • Izzo AA, Coutts AA (2005) Cannabinoids and the digestive tract. Handb Exp Pharmacol 168:573–598

    CAS  PubMed  Google Scholar 

  • Izzo AA, Capasso F, Costagliola A, Bisogno T, Marsicano G, Ligresti A et al (2003) An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. Gastroenterology 125(3):765–774 [see comment]

    CAS  PubMed  Google Scholar 

  • Jacobsson SO, Fowler CJ (2001) Characterization of palmitoylethanolamide transport in mouse Neuro-2a neuroblastoma and rat RBL-2H3 basophilic leukaemia cells: comparison with anandamide. Br J Pharmacol 132(8):1743–1754

    CAS  PubMed  Google Scholar 

  • Jaggar SI, Sellaturay S, Rice AS (1998a) The endogenous cannabinoid anandamide, but not the CB2 ligand palmitoylethanolamide, prevents the viscero-visceral hyper-reflexia associated with inflammation of the rat urinary bladder. Neurosci Lett 253(2):123–126

    CAS  PubMed  Google Scholar 

  • Jaggar SI, Hasnie FS, Sellaturay S, Rice AS (1998b) The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 76(1–2):189–199

    CAS  PubMed  Google Scholar 

  • Jaggar SI, Scott HC, Rice AS (1999) Inflammation of the rat urinary bladder is associated with a referred thermal hyperalgesia which is nerve growth factor dependent. Br J Anaesthiol 83(3):442–448

    CAS  Google Scholar 

  • Jensen BC, Swigart PM, Simpson PC, Jensen BC, Swigart PM, Simpson PC (2009) Ten commercial antibodies for alpha-1-adrenergic receptor subtypes are nonspecific. Naunyn Schmiedebergs Arch Pharmacol 379(4):409–412

    CAS  PubMed  Google Scholar 

  • Jonsson KO, Vandevoorde S, Lambert DM, Tiger G, Fowler CJ (2001) Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide. Br J Pharmacol 133(8):1263–1275

    CAS  PubMed  Google Scholar 

  • Jositsch G, Papadakis T, Haberberger RV, Wolff M, Wess J, Kummer W et al (2009) Suitability of muscarinic acetylcholine receptor antibodies for immunohistochemistry evaluated on tissue sections of receptor gene-deficient mice. Naunyn Schmiedebergs Arch Pharmacol 379(4):389–395

    CAS  PubMed  Google Scholar 

  • Kapur A, Zhao P, Sharir H, Bai Y, Caron MG, Barak LS et al (2009) Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem 284(43):29817–29827

    CAS  PubMed  Google Scholar 

  • Katona I, Sperlagh B, Sik A, Kafalvi A, Vizi ES, Mackie K et al (1999) Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 19(11):4544–4558

    CAS  PubMed  Google Scholar 

  • Katona I, Sperlagh B, Magloczky Z, Santha E, Kofalvi A, Czirjak S et al (2000) GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus. Neuroscience 100(4):797–804

    CAS  PubMed  Google Scholar 

  • Khanolkar AD, Abadji V, Lin S, Hill WA, Taha G, Abouzid K et al (1996) Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. J Med Chem 39(22):4515–4519

    CAS  PubMed  Google Scholar 

  • Lambert DM, Di Marzo V (1999) The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic? Curr Med Chem 6(8):757–773

    CAS  PubMed  Google Scholar 

  • Lambert DM, Vandevoorde S, Diependaele G, Govaerts SJ, Robert AR (2001) Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice. Epilepsia 42(3):321–327

    CAS  PubMed  Google Scholar 

  • Lan R, Gatley J, Lu Q, Fan P, Fernando SR, Volkow ND et al (1999a) Design and synthesis of the CB1 selective cannabinoid antagonist AM281: a potential human SPECT ligand. AAPS Pharmsci 1(2):E4

    CAS  PubMed  Google Scholar 

  • Lan R, Liu Q, Fan P, Lin S, Fernando SR, McCallion D et al (1999b) Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem 42(4):769–776

    CAS  PubMed  Google Scholar 

  • Lichtman AH, Cook SA, Martin BR (1996) Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J Pharmacol Exp Ther 276(2):585–593

    CAS  PubMed  Google Scholar 

  • Lin S, Khanolkar AD, Fan P, Goutopoulos A, Qin C, Papahadjis D et al (1998) Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. J Med Chem 41(27):5353–5361

    CAS  PubMed  Google Scholar 

  • Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A et al (2005) The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 67(1):15–19

    CAS  PubMed  Google Scholar 

  • Loria F, Petrosino S, Mestre L, Spagnolo A, Correa F, Hernangomez M et al (2008) Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. Eur J Neurosci 28(4):633–641

    PubMed  Google Scholar 

  • Lu X, Bartfai T, Lu X, Bartfai T (2009) Analyzing the validity of GalR1 and GalR2 antibodies using knockout mice. Naunyn Schmiedebergs Arch Pharmacol 379(4):417–420

    CAS  PubMed  Google Scholar 

  • Machado Rocha FC, Stefano SC, De Cassia HR, Rosa Oliveira LM, Da Silveira DX, Rosa Oliveira LMQ (2008) Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care 17(5):431–443

    CAS  Google Scholar 

  • Mailleux P, Parmentier M, Vanderhaeghen JJ (1992) Distribution of cannabinoid receptor messenger RNA in the human brain: an in situ hybridization histochemistry with oligonucleotides. Neurosci Lett 143(1–2):200–204

    CAS  PubMed  Google Scholar 

  • Martin RS, Luong LA, Welsh NJ, Eglen RM, Martin GR, MacLennan SJ (2000) Effects of cannabinoid receptor agonists on neuronally-evoked contractions of urinary bladder tissues isolated from rat, mouse, pig, dog, monkey and human. Br J Pharmacol 129(8):1707–1715

    CAS  PubMed  Google Scholar 

  • Martyn CN, Illis LS, Thom J (1995) Nabilone in the treatment of multiple sclerosis. Lancet 345(8949):579

    CAS  PubMed  Google Scholar 

  • Mascolo N, Izzo AA, Ligresti A, Costagliola A, Pinto L, Cascio MG et al (2002) The endocannabinoid system and the molecular basis of paralytic ileus in mice. FASEB J 16(14):1973–1975

    CAS  PubMed  Google Scholar 

  • Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346(6284):561–564 [see comment]

    CAS  PubMed  Google Scholar 

  • Matsuda LA, Bonner TI, Lolait SJ (1993) Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol 327(4):535–550

    CAS  PubMed  Google Scholar 

  • Mazzola C, Medalie J, Scherma M, Panlilio LV, Solinas M, Tanda G et al (2009) Fatty acid amide hydrolase (FAAH) inhibition enhances memory acquisition through activation of PPAR-alpha nuclear receptors. Learn Mem 16(5):332–337

    PubMed  Google Scholar 

  • McMahon SB (1988) Neuronal and behavioural consequences of chemical inflammation of rat urinary bladder. Agents Actions 25(3–4):231–233

    CAS  PubMed  Google Scholar 

  • McMahon SB, Abel C (1987) A model for the study of visceral pain states: chronic inflammation of the chronic decerebrate rat urinary bladder by irritant chemicals. Pain 28(1):109–127

    CAS  PubMed  Google Scholar 

  • Mechoulam R, Fride E (2001) Physiology. a hunger for cannabinoids. Nature 410(6830):763 [comment]

    CAS  PubMed  Google Scholar 

  • Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR et al (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50(1):83–90

    CAS  PubMed  Google Scholar 

  • Merriam FV, Wang ZY, Guerios SD, Bjorling DE, Merriam FV, Z-y W et al (2008) Cannabinoid receptor 2 is increased in acutely and chronically inflamed bladder of rats. Neurosci Lett 445(1):130–134

    CAS  PubMed  Google Scholar 

  • Michel MC, Wieland T, Tsujimoto G, Michel MC, Wieland T, Tsujimoto G (2009) How reliable are G-protein-coupled receptor antibodies? Naunyn Schmiedebergs Arch Pharmacol 379(4):385–388

    CAS  PubMed  Google Scholar 

  • Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365(6441):61–65 [see comment]

    CAS  PubMed  Google Scholar 

  • Murineddu G, Lazzari P, Ruiu S, Sanna A, Loriga G, Manca I et al (2006) Tricyclic pyrazoles. 4. Synthesis and biological evaluation of analogues of the robust and selective CB2 cannabinoid ligand 1-(2′, 4′-dichlorophenyl)-6-methyl-N-piperidin-1-yl-1, 4-dihydroindeno[1, 2-c]pyrazole-3-carboxamide. J Med Chem 49(25):7502–7512

    CAS  PubMed  Google Scholar 

  • Nagy I, Santha P, Jancso G, Urban L, Nagy I, Santha P et al (2004) The role of the vanilloid (capsaicin) receptor (TRPV1) in physiology and pathology. Eur J Pharmacol 500(1–3):351–369

    CAS  PubMed  Google Scholar 

  • Nazif O, Teichman JM, Gebhart GF, Nazif O, Teichman JMH (2007) Neural upregulation in interstitial cystitis. Urology 69(4 Suppl):24–33

    PubMed  Google Scholar 

  • O’Sullivan SE (2007) Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol 152(5):576–582

    PubMed  Google Scholar 

  • O’Sullivan SE, Kendall DA, Randall MD, O’Sullivan SE, Kendall DA, Randall MD (2009) Time-dependent vascular effects of endocannabinoids mediated by peroxisome proliferator-activated receptor gamma (PPARgamma). PPAR Res 2009:425289

    PubMed  Google Scholar 

  • Onaivi ES, Ishiguro H, Gong JP, Patel S, Meozzi PA, Myers L et al (2008) Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Ann NY Acad Sci 1139:434–449

    CAS  PubMed  Google Scholar 

  • Pacheco M, Childers SR, Arnold R, Casiano F, Ward SJ (1991) Aminoalkylindoles: actions on specific G-protein-linked receptors. J Pharmacol Exp Ther 257(1):170–183

    CAS  PubMed  Google Scholar 

  • Pertwee RG (2001) Cannabinoids and the gastrointestinal tract. Gut 48(6):859–867

    CAS  PubMed  Google Scholar 

  • Pertwee RG, Fernando SR (1996) Evidence for the presence of cannabinoid CB1 receptors in mouse urinary bladder. Br J Pharmacol 118(8):2053–2058

    CAS  PubMed  Google Scholar 

  • Pertwee RG, Stevenson LA, Elrick DB, Mechoulam R, Corbett AD (1992) Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine. Br J Pharmacol 105(4):980–984

    CAS  PubMed  Google Scholar 

  • Pertwee RG, Fernando SR, Nash JE, Coutts AA (1996) Further evidence for the presence of cannabinoid CB1 receptors in guinea-pig small intestine. Br J Pharmacol 118(8):2199–2205

    CAS  PubMed  Google Scholar 

  • Peters MF, Scott CW, Peters MF, Scott CW (2009) Evaluating cellular impedance assays for detection of GPCR pleiotropic signaling and functional selectivity. J Biomol Screen 14(3):246–255

    CAS  PubMed  Google Scholar 

  • Pradidarcheep W, Stallen J, Labruyere WT, Dabhoiwala NF, Michel MC, Lamers WH et al (2009) Lack of specificity of commercially available antisera against muscarinergic and adrenergic receptors. Naunyn Schmiedebergs Arch Pharmacol 379(4):397–402

    CAS  PubMed  Google Scholar 

  • Rhee MH, Vogel Z, Barg J, Bayewitch M, Levy R, Hanus L et al (1997) Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase. J Med Chem 40(20):3228–3233

    CAS  PubMed  Google Scholar 

  • Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C et al (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350(2–3):240–244

    CAS  PubMed  Google Scholar 

  • Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C et al (1998) SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 284(2):644–650

    CAS  PubMed  Google Scholar 

  • Robson P (2001) Therapeutic aspects of cannabis and cannabinoids. Br J Psychiatry 178:107–115 [see comment]

    CAS  PubMed  Google Scholar 

  • Rodriguez JJ, Mackie K, Pickel VM (2001) Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. J Neurosci 21(3):823–833

    CAS  PubMed  Google Scholar 

  • Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A et al (1999) Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol 126(3):665–672

    CAS  PubMed  Google Scholar 

  • Ross RA, Craib SJ, Stevenson LA, Pertwee RG, Henderson A, Toole J et al (2002) Pharmacological characterization of the anandamide cyclooxygenase metabolite: prostaglandin E2 ethanolamide. J Pharmacol Exp Ther 301(3):900–907

    CAS  PubMed  Google Scholar 

  • Sade H, Muraki K, Ohya S, Hatano N, Imaizumi Y, Sade H et al (2006) Activation of large-conductance, Ca2+-activated K+ channels by cannabinoids. Am J Physiol Cell Physiol 290(1):C77–C86

    CAS  PubMed  Google Scholar 

  • Saitoh C, Kitada C, Uchida W, Chancellor MB, de Groat WC, Yoshimura N et al (2007) The differential contractile responses to capsaicin and anandamide in muscle strips isolated from the rat urinary bladder. Eur J Pharmacol 570(1–3):182–187

    CAS  PubMed  Google Scholar 

  • Shire D, Calandra B, Rinaldi-Carmona M, Oustric D, Pessegue B, Bonnin-Cabanne O et al (1996) Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor. Biochim Biophys Acta 1307(2):132–136

    PubMed  Google Scholar 

  • Showalter VM, Compton DR, Martin BR, Abood ME (1996) Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278(3):989–999

    CAS  PubMed  Google Scholar 

  • Shu YZ (1998) Recent natural products based drug development: a pharmaceutical industry perspective. J Nat Prod 61(8):1053–1071

    CAS  PubMed  Google Scholar 

  • Sibley WA (1992) Therapeutic claims in multiple sclerosis, 3rd edn. Demos Medical, New York

    Google Scholar 

  • Smart D, Gunthorpe MJ, Jerman JC, Nasir S, Gray J, Muir AI et al (2000) The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol 129(2):227–230

    CAS  PubMed  Google Scholar 

  • Smart D, Jonsson KO, Vandevoorde S, Lambert DM, Fowler CJ, Smart D et al (2002) ‘Entourage’ effects of N-acyl ethanolamines at human vanilloid receptors. Comparison of effects upon anandamide-induced vanilloid receptor activation and upon anandamide metabolism. Br J Pharmacol 136(3):452–458

    CAS  PubMed  Google Scholar 

  • Sugiura T, Kondo S, Kishimoto S, Miyashita T, Nakane S, Kodaka T et al (2000) Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J Biol Chem 275(1):605–612

    CAS  PubMed  Google Scholar 

  • Tokanovic S, Malone DT, Ventura S (2007) Stimulation of epithelial CB1 receptors inhibits contractions of the rat prostate gland. Br J Pharmacol 150(2):227–234

    CAS  PubMed  Google Scholar 

  • Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM (1998) Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83(2):393–411

    CAS  PubMed  Google Scholar 

  • Tsou K, Mackie K, Sanudo-Pena MC, Walker JM (1999) Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocampal formation. Neuroscience 93(3):969–975

    CAS  PubMed  Google Scholar 

  • Tyagi V, Philips BJ, Su R, Smaldone MC, Erickson VL, Chancellor MB et al (2009) Differential expression of functional cannabinoid receptors in human bladder detrusor and urothelium. J Urol 181(4):1932–1938

    CAS  PubMed  Google Scholar 

  • Ueda N, Yamamoto S (2000) Anandamide amidohydrolase (fatty acid amide hydrolase). Prostaglandins Other Lipid Mediat 61(1–2):19–28

    CAS  PubMed  Google Scholar 

  • Wade DT, Robson P, House H, Makela P, Aram J (2003) A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 17(1):21–29

    PubMed  Google Scholar 

  • Wade DT, Makela P, Robson P, House H, Bateman C (2004) Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 10(4):434–441 [see comment]

    CAS  PubMed  Google Scholar 

  • Wahn H, Wolf J, Kram F, Frantz S, Wagner JA, Wahn H et al (2005) The endocannabinoid arachidonyl ethanolamide (anandamide) increases pulmonary arterial pressure via cyclooxygenase-2 products in isolated rabbit lungs. Am J Physiol Heart Circ Physiol 289(6):H2491–H2496

    CAS  PubMed  Google Scholar 

  • Walczak JS, Price TJ, Cervero F (2009) Cannabinoid CB1 receptors are expressed in the mouse urinary bladder and their activation modulates afferent bladder activity. Neuroscience 159(3):1154–1163

    CAS  PubMed  Google Scholar 

  • Wang EC, Lee JM, Ruiz WG, Balestreire EM, von Bodungen M, Barrick S et al (2005) ATP and purinergic receptor-dependent membrane traffic in bladder umbrella cells. J Clin Invest 115(9):2412–2422

    CAS  PubMed  Google Scholar 

  • Westlake TM, Howlett AC, Bonner TI, Matsuda LA, Herkenham M (1994) Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer’s brains. Neuroscience 63(3):637–652

    CAS  PubMed  Google Scholar 

  • Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A et al (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362(9395):1517–1526 [see comment]

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Temple University School of Medicine, 3400 North Broad Street, 715 OMS, Philadelphia, PA, 19140-5104, USA

    Michael R. Ruggieri Sr

Authors
  1. Michael R. Ruggieri Sr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael R. Ruggieri Sr .

Editor information

Editors and Affiliations

  1. Wake Forest University, Medical Center Blvd., Winston-Salem, 27157-1088, North Carolina, USA

    Karl-Erik Andersson

  2. Academic Medical Center, Dept. Pharmacology & Pharmacotherapy, University of Amsterdam, Meibergdreef 15, Amsterdam, 1105 AZ, Netherlands

    Martin C. Michel

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Ruggieri, M.R. (2011). Cannabinoids: Potential Targets for Bladder Dysfunction. In: Andersson, KE., Michel, M. (eds) Urinary Tract. Handbook of Experimental Pharmacology, vol 2011. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-16499-6_20

Download citation

Publish with us

Policies and ethics

Search

Navigation